Our in vitro pharmacology services provide detailed insight into Mechanisms of Action (MOA), biological activity, and therapeutic potency, enabling confident decision-making throughout drug discovery and development. Drive a deeper understanding of the safety and efficacy of your therapeutic candidates with RoukenBio.
Using advanced in vitro pharmacology assays and biologically relevant cellular models, RoukenBio supports the characterization of safety and efficacy across early discovery, lead optimization, and translational development. Our work helps reduce uncertainty, refine therapeutic strategy, and generate robust, decision-ready data aligned to downstream clinical and manufacturing requirements.
Our team of scientific experts has created sophisticated models and tools that are highly adaptable to individual research goals and provide robust and reliable data. Our approach goes beyond merely executing assays under customer direction; we actively collaborate with our customers, providing strategic insights and advise upon alternative approaches to maximize the project value and outcomes.
We have extensive, demonstrated experience working with multiple customers across various products, establishing ourselves as the go-to supplier for outsourced support to conduct in vitro pharmacology studies.
Translational Expertise
Innovative Techniques and Technologies
Advanced Models and Tools
Inducible Expression (IndEx-2)
We link complex methodologies developed during early discovery directly into in vitro pharmacology, ensuring data generated remains relevant as programs progress.
Our assays are designed with downstream application in mind, supporting longer-term assay development, formal characterization, and the development of methods suitable for GMP lot release. This continuity provides customers with a cohesive development pathway, reducing rework and supporting confident progression from early discovery through to clinical and commercial stages.
We link complex methodologies developed during early discovery directly into in vitro pharmacology, ensuring data generated remains relevant as programs progress.
Our assays are designed with downstream application in mind, supporting longer-term assay development, formal characterization, and the development of methods suitable for GMP lot release. This continuity provides customers with a cohesive development pathway, reducing rework and supporting confident progression from early discovery through to clinical and commercial stages.
We integrate advanced instrumentation with high-content methodologies to investigate cellular processes in depth, enabling more informative and predictive in vitro assessment.
Our capabilities extend beyond traditional assays, incorporating kinetic measurements and in vitro immunology readouts such as immune cell activation, cytokine release, and modulation of key cellular factors. These approaches support the development of refined, translational assays and contribute to robust characterization suitable for clinical and commercial application.
Our advanced models and tools support highly relevant in vitro pharmacology assays by incorporating primary cells from both healthy donors and patients.
We operate streamlined processes that allow donor recall for ongoing consistency, alongside the isolation and generation of individual immune cell classes across all major immune classes. This flexibility enables the development of biologically relevant models tailored to specific therapeutic contexts, improving assay predictivity and translational relevance.
IndEx-2 is a proprietary inducible expression assay system designed to assess how antigen expression levels influence the efficacy and safety of targeted therapeutics.
The platform enables controlled expression of one or two antigens, allowing estimation of expression thresholds required for therapeutic activation. By supporting detailed evaluation across development stages, IndEx-2 helps refine targeting strategies and supports smoother transition from early research into clinical application.
RoukenBio partners with drug discovery teams to deliver in vitro pharmacology and immunology services that reduce uncertainty, support translational decision-making, and accelerate program progression. From bespoke assay design to advanced cellular models, we provide the scientific depth and strategic insight needed to tackle complex biological questions and generate data that stands up throughout development.
As a global pharmaceutical contract research organization, RoukenBio provides drug development services to the vast scientific network worldwide. Our scientific partners are based mainly in the USA—particularly in Massachusetts (Boston, Cambridge) and California (San Francisco and San Diego)—Canada (from Vancouver up to Seattle), the UK, and Europe.
